Biodesix partners to bring biopsy test to market
BOULDER — Biodesix Inc. has entered into an agreement with Massachusetts-based Thermo Fisher Scientific to bring a liquid biopsy test to market.
In a press release Tuesday, the Boulder-based cancer testing company said it will produce clinical data from tests with Thermo Fisher’s cancer test that searches blood samples for signs of mutation within 52 genes that could signal the presence of several types of cancer.
In a phone interview, Biodesix CEO David Brumel said Thermo Fisher already has U.S. Food and Drug Administration approval of a tissue-based biopsy but partnered with Biodesix to take its blood-based biopsy through clinical trials.
The company is currently getting paid to run the test in its lab for pharmaceutical companies performing clinical studies before both companies take financial benefits if the test reaches the market.
Brumel said Biodesix is already in contact with the FDA regarding clinical trials and expects to see product approval by the third or fourth quarter of 2020, with approval for use in Medicare programs shortly after.
“This will enable companies that have targeted therapies to be able to talk about our testing to the doctors who are treating the patients and make it easy for anyone to order and get paid for doing this genetic testing,” he said.
Biodesix most recently purchased a lung cancer test and an oncology lab in De Soto, Kansas, from U.K.-based Oncimmune late last month. The company also licensed technology from Montreal-based MRM Proteomics in January to further its lung cancer diagnostics products.
BOULDER — Biodesix Inc. has entered into an agreement with Massachusetts-based Thermo Fisher Scientific to bring a liquid biopsy test to market.
In a press release Tuesday, the Boulder-based cancer testing company said it will produce clinical data from tests with Thermo Fisher’s cancer test that searches blood samples for signs of mutation within 52 genes that could signal the presence of several types of cancer.
In a phone interview, Biodesix CEO David Brumel said Thermo Fisher already has U.S. Food and Drug Administration approval of a tissue-based biopsy but partnered with Biodesix to take its…
This article has been intentionally blurred.
You must purchase a subscription to view the rest of this content.
Want to See More!?
OR
Start your subscription to BizWest, The Business Journal of the Boulder Valley and Northern Colorado, TODAY!
Online access PLUS print versions of all Bizwest publications
40% Off Annual Membership
Now Only $65 (Normally $108)
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year access to daily email newsletter & breaking news alerts.
Online access for one year.
40% Off Annual Membership
Now Only $65 (Normally $108)
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year access to daily email newsletter & breaking news alerts.
Online access PLUS print versions of all Bizwest publications
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
- 1-year access to daily email newsletter & breaking news alerts.
Online access for one year.
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year access to daily email newsletter & breaking news alerts.
Online and print versions of all Bizwest publications PLUS premium access to BizWest Datastore for one year.
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to unlimited downloads from the BizWest Datastore!
- 1-year premium online access to the Breaking Ground website!
- 1-year access to daily email newsletter & breaking news alerts.
Premium access to the BreakingGround site plus online and print versions of all BizWest publications.
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to the Breaking Ground website!
- 1-year access to daily email newsletter & breaking news alerts.
Premium access to the BreakingGround site plus online and print versions of all BizWest publications.
One month subscription includes:
- 1-year premium online access to the Breaking Ground website!
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
- 1-year access to daily email newsletter & breaking news alerts.